Current and Emerging Formulation Strategies for the Effective Transdermal Delivery of HIV Inhibitors

References

• Transdermal drug delivery-technologies, markets and companies. Jain PharmaBiotech Report, (2005). pharmabiotech.ch/reports/tdd/.
   Google Scholar
• Paudel KS Milewski M Swadley CL Brogden NK Ghosh P Stinchcomb AL . Challenges and opportunities in dermal/transdermal delivery. Ther. Deliv.1 (11), 109–131 (2010).
   PubMedGoogle Scholar
• Segal M . Patches, pumps and timed release: new ways to deliver drugs. US FDA Consumer25 (8), 13–15 (2011).
   Google Scholar
• Cadth: Rotigotine transdermal patched (Neupro) for the treatment of Parkinson's disease. Issues Emerg. Health Technol. (112), 1–6 (2008).
   Google Scholar
• Kumar, R Philip, A . Modified transdermal technologies: breaking the barriers of drug permeation via the skin. Trop. J. Pharm. Res.6 (1), 633–644 (2007).
   Web of Science ®Google Scholar
• Shah S . Transdermal drug delivery technology revisited: recent advances. www.Pharmainfo.net.
   Google Scholar
• Bos JD Meinardi MMHM . The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp. Dermatol.9 (3), 165–169 (2000).
   PubMed Web of Science ®Google Scholar
• Takmaz EA Inal Ö Baykara T . Studies on transdermal delivery enhancement of zidovudine. AAPS PharmSciTech10, 88–97 (2009).
   PubMed Web of Science ®Google Scholar
• Patel NA Patel NJ Patel RP . Design and evaluation of transdermal drug delivery system for curcumin as an anti-inflammatory drug. Drug Dev. Ind. Parm35 (2), 234–242 (2009).
   PubMed Web of Science ®Google Scholar
• Nath A Sitruk-Ware R . Parenteral administration of progestins for hormonal replacement therapy. Eur. J. Contracept. Reprod. Health Care14 (2), 88–96 (2009).
   PubMed Web of Science ®Google Scholar
• Aqil M Ali A Sultana Y Najmi A . Fabrication and evaluation of polymeric films for transdermal delivery of pinacidil. Pharmazie59 (8), 631–635 (2004).
   PubMed Web of Science ®Google Scholar
• Cleary G . Medical applications of controlled release. In : Transdermal controlled release systems, LangerD ( Eds). CRC Press, FL, USA203–251 (1984).
   Google Scholar
• Kydonieus A . Controlled Release Technologies. CRC Press, FL, USA (1987).
   Google Scholar
• Chien Y . Transdermal therapeutic system. In : Controlled Drug delivery fundamentals and applications, RobinsonJLeeV ( Eds). Marcel Dekker, Inc., New York, USA524–552 (1987).
   Google Scholar
• Keith A . Polymer matrix consideration for transdermal devices. Drug Dev. Ind. Parm.9, 605–621 (1983).
   Web of Science ®Google Scholar
• Lane T Pettifor A Pascoe S Fiamma A Rees H . Heterosexual anal intercourse increases risk of HIV infection among young South African men. AIDS20 (1), 123–125 (2006).
   PubMed Web of Science ®Google Scholar
• Mahalingam A Simmons AP Ugaonkar SR et al. Vaginal microbicide gel for the delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1. Antimicrob Agents Chemother55 (4), 1650–1660 (2011).
   PubMed Web of Science ®Google Scholar
• Buckheit RW, Jr Snow MJ Fliakas-Boltz V et al. Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates. Antimicrob Agents Chemother41 (4), 831–837 (1997).
   PubMed Web of Science ®Google Scholar
• Buckheit RW, Jr. Roberson JL Lackman-Smith C Wyatt JR Vickers TA Ecker DJ . Potent and specific inhibition of HIV envelope-mediated cell fusion and virus binding by G quartet-forming oligonucleotide (ISIS 5320). AIDS Res. Hum. Retroviruses10 (11), 1497–1506 (1994).
   PubMed Web of Science ®Google Scholar
• Hadgraft J Lane ME . Skin permeation: the years of enlightenment. Int. J. Pharm.305 (1–2), 2–12 (2005).
   PubMedGoogle Scholar
• Lewi P Arnold E Andries K et al. Correlations between factors determining the pharmacokinetics and antiviral activity of HIV-1 non-nucleoside reverse transcriptase inhibitors of the diaryltriazine and diarylpyrimidine classes of compounds. Drugs R D.5 (5), 245–257 (2004).
   PubMedGoogle Scholar
• Buckheit RW, Jr . Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy. Expert Opin. Investig. Drugs13 (8), 933–958 (2004).
   PubMed Web of Science ®Google Scholar
• Mansky LM Temin HM . Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol.69 (8), 5087–5094 (1995).
   PubMed Web of Science ®Google Scholar
• Ojewole E Mackraj I Naidoo P Govender T . Exploring the use of novel drug delivery systems for antiretroviral drugs. Eur. J. Pharm. Biopharm.70, 697–710 (2008).
   PubMed Web of Science ®Google Scholar
• Kuksal A Tiwary A Jain N, S. J . Formulation and in vitro, in vivo evaluation of extended- release matrix tablet of zidovudine: influence of combination of hydrophilic and hydrophobic matrix formers. AAPS PharmSciTech.7 (1), e1–e9 (2006).
   PubMed Web of Science ®Google Scholar
• Oh S Jeong S Park T Lee J . Enhanced transdermal delivery of AZT (Zidovudine) using iontophoresis and penetration enhancer. J. Control. Release51, 161–168 (1998).
   PubMed Web of Science ®Google Scholar
• Costa P Sausa Lobo JM . Evaluation of mathematical models describing drug release from estradiol transdermal systems. Drug Dev. Ind. Pharm.29 (1), 89–97 (2003).
   PubMed Web of Science ®Google Scholar
• Zorbist R Quan D Thomas H Stanworth S . Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system. Pharm. Res.20, 103 (2003).
   PubMed Web of Science ®Google Scholar
• Mukherjee B Mahaoatra S Gupta R Patra B Tiwari A Arora A . A comparison of povidone-ethylcellulose and povidone-eudragit transdermal dexamethasone matrix patches based on in vitro skin permeation. Eur. J. Pharm. Biopharm.59, 475–483 (2005).
   PubMed Web of Science ®Google Scholar
• Jain A Jain P Kurmi J Jain D Jain R et al. (2014) Novel strategies for effective transdermal drug delivery: a review. Crit. Rev. Ther. Drug Carrier Syst.31, 219–272.
   PubMed Web of Science ®Google Scholar
• Thong HY Zhai H Maibach HI . Percutaneous penetration enhancers: an overview. Skin Pharm. Physiol.20 (6), 272–282 (2007).
   PubMed Web of Science ®Google Scholar
• Karande P Mitragotri S . Enhancement of transdermal drug delivery via synergistic action of chemicals. Biochim. Biophys. Acta (BBA) - Biomembranes1788 (11), 2362–2373 (2009).
   PubMed Web of Science ®Google Scholar
• Seki T Kawaguchi T Juni K Sugibayashi K Morimoto Y . Sustained transdermal delivery of zidovudine via controlled release of penetration enhancer. J. Control. Release17 (1), 41–47 (1991).
   Web of Science ®Google Scholar
• Jeong S Lee J Yuk S Lee H . Transdermal delivery system of anti-AIDS virus agent using a biopolymer. Polymer (Korea)20, 347–354 (1996).
   Web of Science ®Google Scholar
• Kim DD Chien YW . Transdermal delivery of dideoxynucleoside-type anti-HIV drugs. 1. Stability studies for hairless rat skin permeation. J. Pharm. Sci.84 (9), 1061–1066 (1995).
   PubMed Web of Science ®Google Scholar
• Kim D-D Kim JL Chien YW . Mutual hairless rat skin permeation-enhancing effect of ethanol/water system and oleic acid. J. Pharm. Sci.85 (11), 1191–1195 (1996).
   PubMed Web of Science ®Google Scholar
• Kim D-D Chien YW (1996) Transdermal delivery of dideoxynucleoside-type anti-HIV drugs. 2. The effect of vehicle and enhancer on skin permeation. J. Pharm. Sci.85, 214–219.
   PubMed Web of Science ®Google Scholar
• Suwanpidokkul N Thongnopnua P Umprayn K . Transdermal delivery of zidovudine (AZT): the effects of vehicles, enhancers, and polymer membranes on permeation across cadaver pig skin. AAPS PharmSciTech5 (3), e48 (2004).
   PubMed Web of Science ®Google Scholar
• N'da DD Breytenbach JC . Synthesis of methoxypoly(ethylene glycol) carbonate prodrugs of zidovudine and penetration through human skin in vitro. J. Pharm. Pharmacol.61 (6), 721–731 (2009).
   PubMed Web of Science ®Google Scholar
• Jain S Tiwary AK Jain NK . PEGylated elastic liposomal formulation for lymphatic targeting of zidovudine. Curr. Drug. Deliv.5 (4), 275–281 (2008).
   PubMedGoogle Scholar
• Dubey V Mishra D Nahar M Jain V Jain NK . Enhanced transdermal delivery of an anti-HIV agent via ethanolic liposomes. Nanomedicine6 (4), 590–596 (2010).
   PubMed Web of Science ®Google Scholar
• Som I Bhatia K Yasir M . Status of surfactants as penetration enhancers in transdermal drug delivery. J. Pharm. Bioallied. Sci.4 (1), 2–9 (2012).
   PubMedGoogle Scholar
• Van Heerden J Breytenbach JC N'da DD Breytenbach JW Du Preez JL . Synthesis and in vitro transdermal penetration of methoxypoly(ethylene glycol) carbonate and carbamate derivatives of lamivudine (3TC). Med. Chem.6 (2), 91–99 (2010).
   PubMed Web of Science ®Google Scholar
• Mukherji E Millenbaugh NJ Au JL . Percutaneous absorption of 2’,3’-dideoxyinosine in rats. Pharm. Res.11 (6), 809–815 (1994).
   PubMed Web of Science ®Google Scholar
• Kim DD Chien YW . Transdermal delivery of zalcitabine: in vitro skin permeation study. AIDS9 (12), 1331–1336 (1995).
   PubMed Web of Science ®Google Scholar
• Saunders J Davis H Coetzee L Botha S Kruger A Grobler A . A novel skin penetration enhancer: evaluation by membrane diffusion and confocal microscopy. J. Pharm. Pharm. Sci.2 (3), 99–107 (1999).
   PubMed Web of Science ®Google Scholar
• Oh SY Jeong SY Park TG Lee JH . Enhanced transdermal delivery of AZT (Zidovudine) using iontophoresis and penetration enhancer. J. Control. Release51 (2–3), 161–168 (1998).
   PubMed Web of Science ®Google Scholar
• Narishetty STK Panchagnula R . Effect of l-menthol and 1,8-cineole on phase behavior and molecular organization of SC lipids and skin permeation of zidovudine. J. Control. Release102 (1), 59–70 (2005).
   PubMed Web of Science ®Google Scholar
• Kararli TT Kirchhoff CF Penzotti Jr SC . Enhancement of transdermal transport of azidothymidine (AZT) with novel terpene and terpene-like enhancers: in vivo-in vitro correlations. J. Control. Release34 (1), 43–51 (1995).
   Web of Science ®Google Scholar
• Riviere J Heit M . Electrically-assisted transdermal drug delivery. Pharm. Res.14 (6), 687–697 (1997).
   PubMed Web of Science ®Google Scholar
• Dhote V Bhatnagar P Mishra PK Mahajan SC Mishra DK . Iontophoresis: a potential emergence of a transdermal drug delivery system. Sci. Pharm.80 (1), 1–28 (2012).
   PubMedGoogle Scholar
• Indermun S Luttge R Choonara YE et al. Current advances in the fabrication of microneedles for transdermal delivery. J. Control. Release185C, 130–138 (2014).
   Google Scholar
• Zhu Z Luo H Lu W et al. Rapidly dissolvable microneedle patches for transdermal delivery of exenatide. Pharm. Res31 (12), 3348–3360 (2014).
   PubMed Web of Science ®Google Scholar
• Pierre MB Rossetti FC . Microneedle-based drug delivery systems for transdermal route. Curr. Drug Targets15 (3), 281–291 (2014).
   PubMed Web of Science ®Google Scholar
• Donnelly RF Morrow DI Mccrudden MT et al. Hydrogel-forming and dissolving microneedles for enhanced delivery of photosensitizers and precursors. Photochem. Photobiol.90 (3), 641–647 (2014).
   PubMed Web of Science ®Google Scholar
• Zhang X Wu Y Hong Y Zhu X Lin L Lin Q . Preparation and evaluation of dl-praeruptorin A microemulsion based hydrogel for dermal delivery. Drug. Deliv. (2014).
   Google Scholar
• Elnaggar YS El-Refaie WM El-Massik MA Abdallah OY . Lecithin-based nanostructured gels for skin delivery: an update on state of art and recent applications. J. Control. Release180, 10–24 (2014).
   PubMed Web of Science ®Google Scholar
• Dragicevic-Curic N Winter S Stupar M et al. Temoporfin-loaded liposomal gels: viscoelastic properties and in vitro skin penetration. Int. J. Pharm.373 (1–2), 77–84 (2009).
   PubMedGoogle Scholar
• Watson KM Yang L Buckheit Jr RW . Development of dual-acting pyrimidinediones as novel and highly potent topical anti-HIV microbicides. Antimicrob. Agents Chemother.55 (11), 5243–5254 (2011).
   PubMed Web of Science ®Google Scholar
• Buckheit Jr RW Watson K Fliakas-Boltz V et al. SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus Type 1 (HIV-1) that also inhibits HIV-2. Antimicrob. Agents Chemother.45 (2), 393–400 (2001).
   PubMed Web of Science ®Google Scholar
• Sassi AB Mccullough KD Cost MR Hillier SL Rohan LC . Permeability of tritiated water through human cervical and vaginal tissue. J. Pharm. Sci.93 (8), 2009–2016 (2004).
   PubMed Web of Science ®Google Scholar
• Padula C Nicoli S Colombo P Santi P . Single-layer transdermal film containing lidocaine: modulation of drug release. Eur. J. Pharm. Biopharm.66 (3), 422–428 (2007).
   PubMed Web of Science ®Google Scholar
• Cannon CL Neal PJ Southee JA Kubilus J Klausner M . New epidermal model for dermal irritancy testing. Toxicol. In Vitro8 (4), 889–891 (1994).
   PubMed Web of Science ®Google Scholar
• Ham AS Lustig W Yang L Boczar A Buckheit KW et al. In vitro and ex vivo evaluations on transdermal delivery of the HIV inhibitor IQP-0410. PLoS ONE8 : e75306 (2013).
   PubMed Web of Science ®Google Scholar
• Budhian A Siegel SJ Winey KI . Controlling the in vitro release profiles for a system of haloperidol-loaded PLGA nanoparticles. Int. J. Pharm.346 (1–2), 151 (2008).
   PubMed Web of Science ®Google Scholar
• Li Y-P Pei Y-Y Zhang X-Y et al. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J. Control. Release71 (2), 203 (2001).
   PubMed Web of Science ®Google Scholar
• Singh A Aboul-Enein H . Advantages of USP apparatus IV (flow-through cell apparatus) in dissolution studies. Iranian Chemical Society3 (3), 220–222 (2006).
   Web of Science ®Google Scholar
• Scheindlin S . Transdermal drug delivery: PAST, PRESENT, FUTURE. Mol. Interv.4 (6), 308–312 (2004).
   PubMed Web of Science ®Google Scholar
• Turpin J: Considerations and development of topical microbicides to inhibit the sexual transmission of HIV. Expert Opin. Investig. Drugs11 (8), 1007–1097 (2002).
   Web of Science ®Google Scholar
• Harrison P Rosenberg Z Bowcut J . Topical microbicides for disease prevention: status and challenges. Clin. Infect. Dis.36 (10), 1290–1294 (2003).
   PubMed Web of Science ®Google Scholar
• Woolfson AD Malcolm RK Morrow RJ Toner CF Mccullagh SD . Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicideInt. J. Pharm.325 (1–2), 82–89 (2006).
   PubMed Web of Science ®Google Scholar
• Gupta KM Pearce SM Poursaid AE et al. Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1. J. Pharm. Sci.97 (10), 4228–4239 (2008).
   PubMed Web of Science ®Google Scholar
• Johnson TJ Clark MR Albright TH et al. A 90-Day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis. Antimicrob. Agents Chemother.56 (12), 6272–6283 (2012).
   PubMed Web of Science ®Google Scholar
• Singer R Mawson P Derby N et al. An intravaginal ring that releases the NNRTI MIV-150 reduces SHIV transmission in macaques. Sci. Transl. Med.4 (150), 1–8 (2012).
   Web of Science ®Google Scholar
• Mcconville C Friend DR Clark MR Malcolm K . Preformulation and development of a once-daily sustained-release tenofovir vaginal tablet tablet containing a single excipient. J. Pharm. Sci.102 (6), 1859–1868 (2013).
   PubMed Web of Science ®Google Scholar
• Marcus JL Glidden DV Mcmahan V et al. Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men. PLoS ONE9 (3), e91513 (2014).
   PubMed Web of Science ®Google Scholar
• Cohen MS Chen YQ Mccauley M et al. Prevention of HIV-1 Infection with early antiretroviral therapy. N. Engl. J. Med.365 (6), 493–505 (2011).
   PubMed Web of Science ®Google Scholar
• Yeni PG Hammer SM Hirsch MS et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. Top HIV Med.292 (2), 251–265 (2004).
   Google Scholar
• Carpenter CC Cooper DA Fischl MA et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA283 (3), 381–390 (2000).
   PubMed Web of Science ®Google Scholar
• Richman DD . HIV therapeutics. Science (New York, NY)272 (5270), 1886–1888 (1996).
   Google Scholar
• Trabattoni D Lo Caputo S Biasin M et al. Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients. Clin. Diagn. Lab. Immunol.9 (5), 1114–1118 (2002).
   PubMedGoogle Scholar